We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
-0.05%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$17.5B
AUM Growth
-$4.53B
(-21%)
Cap. Flow
-$3.73B
Cap. Flow
% of AUM
-21.26%
Top 10 Holdings %
Top 10 Hldgs %
49.23%
Holding
203
New
48
Increased
29
Reduced
30
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$292M |
| 2 |
KKR & Co
KKR
|
+$280M |
| 3 |
Roivant Sciences
ROIV
|
+$248M |
| 4 |
Mastercard
MA
|
+$138M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EXAS
Exact Sciences
EXAS
|
+$650M |
| 2 |
CYBR
CyberArk
CYBR
|
+$470M |
| 3 |
Salesforce
CRM
|
+$334M |
| 4 |
Nasdaq
NDAQ
|
+$290M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.56% |
| 2 | Financials | 12.21% |
| 3 | Technology | 11.18% |
| 4 | Consumer Discretionary | 5.09% |
| 5 | Industrials | 3.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Assembly Biosciences
ASMB
$531M
| $34.1M | 0.19% |
1,227,590
| – | – |
|
|
JOYY
52
JOYY Inc
JOYY
$3.53B
| $33.8M | 0.19% |
578,200
| – | – |
|
53
NetEase
NTES
$84.1B
| $32.6M | 0.19% |
+291,219
| New | +$36.1M |
|
|
NVO
54
Novo Nordisk
NVO
$223B
| $28.7M | 0.16% |
+782,000
| New | +$37.1M |
|
|
BITW
55
Bitwise 10 Crypto Index ETF
BITW
$614M
| $26.9M | 0.15% |
603,000
-2,782,500
| -82% | -$141M |
|
|
PCSC
56
Perceptive Capital Solutions
PCSC
$123M
| $24.7M | 0.14% |
2,250,000
| – | – |
|
57
Royalty Pharma
RPRX
$25.8B
| $23.6M | 0.13% |
+493,000
| New | +$21.6M |
|
58
Minerva Neurosciences
NERV
$199M
| $14.2M | 0.08% |
2,365,000
| – | – |
|
59
Ceco Environmental
CECO
$4.67B
| $13.9M | 0.08% |
+234,000
| New | +$15.1M |
|
60
Avalo Therapeutics
AVTX
$1.02B
| $13.7M | 0.08% |
+916,000
| New | +$14.3M |
|
61
CALL
CG Oncology
CGON
$6.34B
| $13.5M | 0.08% |
+200,000
| New | +$11.3M |
|
62
GDS Holdings
GDS
$6.24B
| $11.8M | 0.07% |
+292,000
| New | +$12.5M |
|
|
MAZE
63
Maze Therapeutics
MAZE
$1.56B
| $11.1M | 0.06% |
+373,000
| New | +$16.5M |
|
64
Teva Pharmaceuticals
TEVA
$37.3B
| $10.7M | 0.06% |
354,000
+314,000
| +785% | +$10.1M |
|
65
FormFactor
FORM
$8.23B
| $5.48M | 0.03% |
+56,500
| New | +$4.86M |
|
66
MasTec
MTZ
$26B
| $5.47M | 0.03% |
+17,000
| New | +$4.6M |
|
67
Entegris
ENTG
$21.1B
| $5.33M | 0.03% |
+45,500
| New | +$5.38M |
|
68
Citigroup
C
$217B
| $5.33M | 0.03% |
+47,000
| New | +$5.35M |
|
|
VNET
69
VNET Group
VNET
$2.1B
| $5.23M | 0.03% |
623,347
-5,662,039
| -90% | -$60M |
|
70
Hyatt Hotels
H
$18B
| $5.18M | 0.03% |
+36,000
| New | +$5.71M |
|
71
Western Alliance Bancorporation
WAL
$8.99B
| $5.17M | 0.03% |
+73,000
| New | +$6.08M |
|
72
Timken Company
TKR
$9.57B
| $5.13M | 0.03% |
+51,000
| New | +$5.07M |
|
73
Flex
FLEX
$43.7B
| $5.11M | 0.03% |
+78,000
| New | +$4.99M |
|
74
S&P Global
SPGI
$133B
| $5.1M | 0.03% |
+12,000
| New | +$5.57M |
|
75
Littelfuse
LFUS
$10.1B
| $5.09M | 0.03% |
+15,000
| New | +$4.87M |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
Farallon Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Farallon Capital Management held 203 positions worth $17.5B, down 21% from $22.1B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Farallon Capital Management withdrew a net $3.73B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 43% a quarter earlier, followed by Financials and Technology.
Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.
- Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
- Farallon Capital Management added most to Broadcom in Q1 2026, an estimated $292M increase.
- Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
- Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
- Farallon Capital Management's ten largest holdings make up 49% of its $17.5B portfolio in Q1 2026.
- Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
- Farallon Capital Management's portfolio value fell 21% quarter-over-quarter to $17.5B.
Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.